ArticleNeuro-oncology advances

Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.

Tyler A Lanman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.